Aug 19- The U.S. government has extended a contract with Cytori Therapeutics to develop a cell-derived treatment for burns, the company said on Tuesday. The government's Biomedical Advanced Research and Development Authority will provide up to $20.4 million to fund early development and costs associated with a clinical trial.» Read More
CNBC's Meg Tirrell reports Vertex Pharmaceuticals' cystic fibrosis combination of Kalydeco and Lumacaftor has expanded their patient population.
CNBC's Meg Tirell reports Vertex Pharmaceuticals' treatment for cystic fibrosis has succeeded in late stage trials. Vertex will now file applications for U.S. and Europe approval in Q4.
Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.
CNBC's Meg Tirrell reports on everything investors need to know about Vertex Pharmaceuticals' upcoming data release on a combination of drugs for cystic fibrosis.
AstraZeneca has invested $240 million in Moderna Therapeutics to license its technology, which uses messenger RNA therapy to fight cancer.
Medtronic announced that it has agreed to purchase Dublin, Ireland's Covidien for $42.9 billion in cash and stock. CNBC's Meg Tirrell discusses why this deal may be more about taxes than medical devices.
Medtronic bought Covidien for $42.9 billion. Shagun Chadha, CRT Capital Group, discusses what this means for investors and explains the tax savings component of the transaction.
CNBC's Meg Tirrell reports Merck is buying Idenix Pharmaceuticals for $3.85 billion. CNBC contributor Herb Greenberg provides insight on the important deal.
New diet pill drug Contrave is expected to be approved by the FDA this week, reports CNBC's Meg Tirrell.
A new Clovis cancer drug has been associated with high blood sugar and linked to diabetes in trial. CEO Patrick J. Mahaffy, Clovis Oncology, weighs in on the recent report.
Clovis Oncology CEO Patrick J. Mahaffy, talks about competing with larger companies like AstraZeneca when it comes to new cancer drugs. You compete on data, he says.
CNBC biotech & pharma reporter Meg Tirrell talks to Richard Pazdur, the FDA's cancer czar about how far we've come in cancer treatment, breakthrough designations and if chemotherapy will soon be a thing of the past.
In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.
The big topic at this year's cancer care conference ASCO will be immunotherapy drugs. CNBC's Meg Tirrell explains how these drugs work.
Valeant is upping its offer for Allergan in a proposal that could now be worth more than $50 billion, reports CNBC's Meg Tirrell.
Silviu Itescu, CEO of Mesoblast, highlights sources of growth that may propel stem-cell therapy into a multi billion-dollar market by 2020.
Discussing hot picks in the biotech space, with Matthew Roden, UBS executive director.
May 14- Prima BioMed Ltd said its experimental lead treatment improved survival in some ovarian cancer patients without the disease worsening. CVac, like Dendreon Corp's prostate cancer vaccine Provenge, is a form of immunotherapy that stimulates the patient's immune system to target and destroy tumors.
CNBC's Seema Mody reveals what stocks and sectors are driving the Nasdaq rally today.
CNBC's Meg Tirrell speaks to Ken Frazier, Merck chaiman & CEO, about selling the company's consumer unit to Bayer. Frazier also gives his stance on mega-mergers and U.S corporate tax rate.